RVX-208 is a potent BET bromodomain antagonist with IC50 of 0.510 µM for BD2, with approximately 170-fold selectivity over BD11,2. Increases apolipoprotein A-1 and HDL cholesterol in vitro and in vivo3. Reduces atherosclerosis4.
* VAT and and shipping costs not included. Errors and price changes excepted